Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.46 |
| ▸ | CNR1 | P21554 | 6/20 | 0.43 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437268 | 0.89 | DYRK1A (0.60) | KCNH2DYRK1AKDM4CCNR1CNR2 | |
| SCHEMBL7291968 | 0.80 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL12485461 | 0.80 | CNR1 (0.48) | KDM4CCNR1CNR2 | |
| SCHEMBL24437195 | 0.79 | CNR1 (0.42) | KCNH2DYRK1AKDM4CCNR1CNR2 | |
| SCHEMBL24437300 | 0.77 | DYRK1A (0.51) | KCNH2DYRK1AKDM4CPTGER4 | |
| SCHEMBL15742957 | 0.76 | CNR2 (0.61) | KDM4CCNR1CNR2 | |
| SCHEMBL24437217 | 0.75 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL2053427 | 0.75 | CNR2 (0.55) | DYRK1AKDM4CCNR1CNR2 | |
| SCHEMBL30421188 | 0.74 | LMNA (0.64) | CNR1CNR2 | |
| SCHEMBL3105128 | 0.74 | CNR1 (0.72) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | ORAI1, CACNA1E, ORAI3 | KCNH2 99/4885DYRK1A 1144/4885KDM4C 2563/4885 |
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | KCNH2 69/4885DYRK1A 4541/4885KDM4C 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.